{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-126067","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.279584+00:00","generated_at":"2026-06-21T06:07:24.934701+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Theravance Biopharma CFO Andrew Hindman to depart Dec 31; Aziz Sawaf named successor","bullets":["Andrew Hindman, SVP and CFO, will leave on December 31, 2022.","Aziz Sawaf appointed CFO effective Jan 1, 2023; previously VP of Finance since Oct 2021.","Sawaf joined Theravance in 2014; prior roles at Gilead Sciences, Amgen, and consulting.","Sawaf holds CFA charter, MBA from USC, and MBEE from Johns Hopkins University."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-126067","json":"https://secwatch.observer/filing/0001104659-22-126067.json","markdown":"https://secwatch.observer/filing/0001104659-22-126067.md","text":"https://secwatch.observer/filing/0001104659-22-126067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/tm2232423d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:07:24.934701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fd3487702","claim":"Andrew A. Hindman changed role as Senior Vice President and Chief Financial Officer at Theravance Biopharma, Inc..","evidence_excerpt":"Andrew A. Hindman, Senior Vice President and Chief Financial Officer, will transition from the Company on December 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"will transition"},{"label":"Role","value":"Senior Vice President and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f4fb6618fd","claim":"Aziz Sawaf was appointed as Chief Financial Officer at Theravance Biopharma, Inc..","evidence_excerpt":"The Company has appointed Aziz Sawaf, CFA as the Company’s Chief Financial Officer, effective immediately following Mr. Hindman’s departure.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}